Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
NCT04040205
Recruiting
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or discontinuation criteria are met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Mayo Clinic, Jacksonville, Florida +3 locations
Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Register for Updates
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
NCT05025423
Recruiting
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Mantle Cell Lymphoma
Register for Updates
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
NCT05780879
Recruiting
The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Secondary Acute Myeloid Leukemia
Register for Updates
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT06110572
Recruiting
This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher dose radiation to known areas of cancer (hypofractionated radiation therapy \[H-RT\]) combined with atezolizumab and chemotherapy (carboplatin \& etoposide) in treating patients with small cell lung cancer that has spread to disease sites outside of the lung (extensive stage). Extensive stage disease has historically been treated with chem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Register for Updates
UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
NCT01401998
Recruiting
In 2005, The University of Alabama at Birmingham established a NIDDK-funded, interdisciplinary center of excellence in PKD-related research, with specific emphasis on recessive PKD. In the previous Core Center award period, we developed a Core Resource to capture clinical and mutational data for ARPKD patients ("Core A: ARPKD Clinical and Genetic Resource", NCT00575705). However, studies in the last several years have demonstrated that ARPKD and other single gene disorders characterized by renal... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/18/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Register for Updates
Quantifying Energetic Demands of Walking for People With Cerebral Palsy
NCT04303078
Recruiting
The purpose of this study is to examine the underlying mechanisms that contribute to high energy costs for people with cerebral palsy (CP) as they walk. The investigators will characterize the cost landscape of children with CP, quantifying the magnitude of cost (net nondimensional oxygen consumption) associated with walking and common sub-tasks of walking, such as supporting and stabilizing the body.
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
06/18/2024
Locations: Gillette Children's Specialty Healthcare, Saint Paul, Minnesota
Conditions: Cerebral Palsy
Register for Updates
Mode of Exercise and Bone Biomarkers in Older Veterans
NCT05266976
Recruiting
Adults are often encouraged to exercise to maintain or improve bone health. However, there is evidence that exercise does not always lead to increases in bone mass, and exercise could lead to bone loss under certain conditions. Endurance exercise can increase bone resorption following an exercise bout, which may explain why bone does not always favorably adapt to exercise, but it is unclear if this also happens with resistance exercise. Further, it is not known how exercise training influences b... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Aging, Musculoskeletal Diseases, Osteoporosis
Register for Updates
Trial of a Culturally Informed Brief Intervention to Reduce Alcohol Related Health Disparities and Treatment Inequities Among Latinxs
NCT05800899
Recruiting
This Stage II Randomized Efficacy Trial will compare the effectiveness of a theoretically informed and culturally responsive brief motivational intervention to a non-adapted brief intervention among non-treatment seeking Latinxs admitted for medical treatment of an injury who engage in at risk drinking or were drinking at the time of their injury. The culturally informed brief motivational intervention (CI-BMI) increases autonomous motivation to engage in protective drinking behavior and reduce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University Medical Center of El Paso, El Paso, Texas
Conditions: Alcohol Use Disorder
Register for Updates
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
NCT06207370
Recruiting
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Babesiosis
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Goodyear, Arizona +95 locations
Conditions: Neoplasms
Register for Updates
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
NCT04338048
Recruiting
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease. In the last decade, it has become more widely appreciated that the disease course begins in childhood. However, evidence-based guidelines on how to manage and approach children diagnosed with or at-risk for of ADPKD are lacking. Overall, there is insufficient data on the clinical course during childhood. The study intends to ge... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/18/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: ADPKD
Register for Updates
nCCR for Chemotherapy Related Cognitive Impairment Randomized Study
NCT05283629
Recruiting
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
06/18/2024
Locations: Center for Cognitive Medicine at Vanderbilt University, Nashville, Tennessee
Conditions: Chemo-brain, Chemotherapy-Related Cognitive Impairment
Register for Updates